Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation myocardial infarction

Nikolaos Stalikas, Andreas S. Papazoglou, Efstratios Karagiannidis, Eleftherios Panteris, Dimitrios Moysidis, Stylianos Daigos, Vasileios Anastasiou, Vasiliki Patsiou, Triantafyllia Koletsas, George Sofidis, Georgios Sianos and George Giannakoulas*

Abstract

Background: Stress induced hyperglycemia (SIH) is common among patients with ST-elevation myocardial infarction (STEMI), even in patients without diabetes mellitus. However, evidence regarding its role on the angiographic outcomes and the prognosis of patients presenting with STEMI is scarce.

Methods: This study included 309 consecutively enrolled STEMI patients undergoing primary percutaneous coronary intervention (pPCI). Patients were diagnosed with SIH if blood glucose on admission was > 140 mg/dl. Also, patients had to fast for at least 8 hours before blood sampling. The objective was to assess whether SIH was associated with major adverse cardiovascular and cerebrovascular (MACCE) events and explore its relationship with angiographic predictors of worse prognosis such as poor initial TIMI flow, intracoronary thrombus burden, distal embolization, and presence of residual thrombus after pPCI.

Results: SIH in diabetic and non-diabetic patients was associated with a higher incidence of LTB (aOR = 2.171, 95% CI 1.27–3.71), distal embolization (aOR = 2.71, 95% CI 1.51–4.86), and pre-procedural TIMI flow grade = 0 (aOR = 2.69, 95% CI 1.43–5.04) after adjusting for relevant clinical variables. Importantly, during a median follow-up of 1.7 years STEMI patients with SIH with or without diabetes experienced increased occurrence of MACCE both in univariate (HR = 1.92, 95% CI 1.19–3.01) and multivariate analysis (aHR = 1.802, 95% CI 1.01–3.21).

Conclusions: SIH in STEMI patients with or without diabetes was independently associated with increased MACCE. This could be attributed to the fact that SIH was strongly correlated with poor pre-procedural TIMI flow, LTB, and distal embolization. Large clinical trials need to validate SIH as an independent predictor of adverse angiographic and clinical outcomes to provide optimal individualized care for patients with STEMI.

Keywords: STEMI, Stress induced hyperglycemia, Diabetes, Thrombus, Distal embolization

Introduction
Stress induced hyperglycemia (SIH) constitutes a transient elevation of blood glucose in the setting of acute illness, including ST segment elevation myocardial infarction (STEMI) [1]. The American Heart Association (AHA) Scientific Statement on Hyperglycemia and Acute
Coronary Syndrome recommended that SIH can be diagnosed in patients presenting with STEMI and blood glucose on admission > 140 mg/dl [2].

SIH is associated with increased short and long term major adverse cardiovascular events in patients with STEMI irrespective of the presence of diabetes [3–5]. However, the metabolic milieu in which SIH emerges during epicardial coronary artery thrombosis remains poorly understood. Emerging evidence suggests that acute elevation of blood glucose levels during stress is caused primarily due to acute insulin resistance and upregulation of the metabolic pathways of gluconeogenesis and glycogenolysis [6]. This neuroendocrine dysregulation hampers mitochondrial function and leads to an excessive oxidative stress response. Through this complex pathophysiology, SIH is correlated with a pro-coagulative state, vascular inflammation, and adverse cardiac remodeling [7–10].

Hence, since increased oxidative stress and inflammation during SIH could theoretically produce poor angiographic outcomes, potentially related to increased thrombus burden (TB), distal embolization, and presence of residual thrombus after primary percutaneous coronary intervention (PPCI), an individualized approach for the treatment of this specific high-risk sub-group of STEMI patients is necessary. Yet, intensive insulin therapy studies have failed to show a difference in mortality between insulin-treated and non-insulin treated patients with SIH and acute myocardial infarction [11, 12]. A recent study reported that thrombus aspiration (TA), although not routinely recommended by current ESC guidelines might be beneficial in this subgroup of STEMI patients, as it was associated with lower mortality [13, 14].

To date, only a few studies have evaluated the association between stress hyperglycemia and angiographic predictors of adverse clinical outcomes [15, 16]. The aim of this study was to assess the association of SIH with major adverse cardiovascular and cerebrovascular events (MACCE) and evaluate the effects of SIH on angiographic findings known to be linked with worse prognosis, such as Thrombolysis In Myocardial Infarction (TIMI) flow prior to PPCI, intracoronary TB, distal embolization, and presence of residual thrombus after PPCI in STEMI patients.

Methods

Study design
This post-hoc analysis of the prospective CorLipid Trial (NCT04580173) aimed to investigate the association of stress hyperglycemia with adverse angiographic and clinical outcomes of patients with STEMI. The study protocol has been approved by the Scientific Committee of AHEPA University Hospital (Protocol number 321/2019) and the detailed protocol has been previously described [17]. Every trial procedure was conducted according to the principles set by the declaration of Helsinki. Each participant provided written informed consent before being enrolled in the study.

Eligibility criteria
This study included consecutively enrolled patients with STEMI undergoing coronary angiography in a tertiary academic hospital during the time range of July 2019 to May 2021. Exclusion criteria of the study were: (i) cardiopulmonary arrest upon admission, (ii) patient fasted < 8 h (iii) missing glycemic values on admission, (iv) late presentation of STEMI (> 12 h of pain onset) or thrombolyis.

Data sources
Angiographic and laboratory characteristics were recorded for every study participant. All blood samples were collected prior to coronary angiography and were analyzed immediately in the in-house clinical laboratory with standard assays.

Definitions
The diagnosis of STEMI was based on clinical symptoms of myocardial ischemia, electrocardiographic findings consistent with STEMI, and increased high sensitivity troponin values, according to the criteria of the Fourth Universal Definition of Myocardial Infarction [18]. SIH was defined as admission glucose values (AGV) greater than 140 mg/dl (7.8 mmol/L) as defined by AHA [2]. Patients with DM were defined by: (a) administration of any anti-diabetic medication; or (b) diagnostic code of DM (International Classification of Diseases-10) in at least one hospital admission or any previous physician-assigned DM diagnosis; or (c) HbA1c value measured during hospitalization above 6.5% (48 mmol/mol).

 Coronary angiography and angiographic outcomes
Prior to performing PPCI, each patient received guide-line-directed pharmaceutical therapy, including unfractionated heparin (80 IU/kg) and a loading dose of aspirin (325 mg). The choice of P2Y12 inhibitor, ticagrelor (180 mg), prasugrel (60 mg) or clopidogrel (600 mg) was at the discretion of the treating physician [19]. Coronary angiograms were analyzed by two experienced interventional cardiologists in a blinded manner. Percentage of diameter stenosis and lesion length were also calculated using quantitative coronary angiography. Patients with pre-procedural TIMI Flow grade 0 were considered to have poor initial TIMI Flow. Angiographic TB was evaluated according to the modified TIMI thrombus classification scale [20]. Based on this classification, patients...
with TIMI Grade 5 thrombus were reclassified to another thrombus category (G0–G4) after flow achievement with either guidewire crossing or a small non-influenced balloon. Patients with TIMI grades G0–G3 were considered as patients with small thrombus burden (STB), whereas patients with thrombus grade G4 were defined to have large thrombus burden (LTB) [21]. Furthermore, post-procedural antegrade coronary flow was evaluated based on TIMI classification. A patient was considered to have angiographically evident residual thrombus, if modified TIMI thrombus grades G2–G4 were present post-procedurally [22]. The presence of distal embolization or myocardial no-reflow phenomenon were also recorded [23].

Clinical outcomes definition and follow-up data
The clinical endpoint was a composite of any major adverse cardiovascular and cerebrovascular event (MACCE), defined as the composite of cardiovascular death, stroke, major bleeding, and CVD-related hospitalizations. If a patient suffered several MACCEs during study follow-up, only one was counted in the calculation of MACCE occurrence. Follow-up data on clinical outcomes were collected by trained independent investigators through telephonic or in-person interviews with the study participants. The vital status of patients was also verified by telephonic follow-up or by accessing the Greek Civil Registration System.

Statistical analysis
Continuous variables are presented as means with standard deviations (SD) and compared using the Mann Whitney U test. Categorical variables are presented as frequencies with percentages and compared via the Pearson chi-square test. Univariable logistic regression analyses were carried out to clarify the association of demographic and clinical baseline characteristics including SIH with angiographic outcomes. The variables with p value <0.1 were later inserted into multivariable regression models to identify independent predictors of adverse angiographic outcomes. Stratified bootstrapping was used to account for the non-parametric nature of the data.

Kaplan Meier survival curves were developed to investigate the association of SIH with MACCE occurrence. Univariable Cox regression analyses were performed to identify significant predictors of MACCE occurrence among the clinically relevant parameters: SIH, baseline clinical, demographic, and angiographic characteristics. The multivariable Cox regression hazard model was developed by forcing into the multivariable analysis clinically relevant baseline covariates and variables that were univariably significantly associated with MACCE occurrence [age, gender, body mass index (BMI), smoking history, hypertension, DM, dyslipidemia, chronic kidney disease (CKD) and peripheral vascular disease]. The generated adjusted hazard ratios (aHR) are presented along with their respective 95% confidence intervals (CI). A two-sided p-value of less than 0.05 was considered statistically significant. All analyses were conducted through the SPSS v26 (SPSS software, Chicago, IL, USA).

Results
From July 2019 to May 2021 a total of 653 patients with STEMI were screened for eligibility. Of those, 309 patients (248 males, 61 females) fulfilled the inclusion criteria (Study Flow Diagram in Additional file: Fig. S1) and were included in the analysis. Specifically, 121 STEMI patients (39.2%) had AGV more than 140 mg/dl, and a fasting period of at least 8 h. These patients were diagnosed with SIH. The baseline clinical and demographic characteristics of our population are detailed in Table 1. The mean age of the patients was 60.4 ± 12.0 years, and 80.3% were male. Of the baseline demographic and clinical characteristics detailed in Table 1, age, gender, BMI, DM, dyslipidemia, and CKD prevalence differed significantly among patients with and without SIH, while mean glucose, creatinine and triglyceride levels were higher in patients with SIH (p values < 0.05).

Stress hyperglycemia and angiographic outcomes
Analysis of the angiographic outcomes according to the presence or not of SIH showed that pre- and post-procedural TIMI flow was significantly lower in patients with SIH (Table 2). LTB and distal embolization occurred more frequently in patients with SIH.

Univariate logistic regression analyses showed that patients with SIH were more likely to have distal embolization, LTB and pre-procedural TIMI flow = 0 (Table 2). In bootstrapped multivariable logistic regression models adjusted for age, gender, Hypertension, DM, dyslipidemia, CKD, smoking, Peripheral Vascular Disease and BMI, SIH was an independent predictor of distal embolization (aOR = 2.71, 95% CI 1.51–4.86), LTB (aOR = 2.17, 95% CI 1.27–3.71), and pre-procedural TIMI flow = 0 (aOR = 2.69, 95% CI 1.43–5.04) irrespective of the presence of DM (Table 3). SIH did not affect the occurrence of angiographically evident residual thrombus, no-reflow phenomenon or worse post-procedural TIMI flow.

Survival analysis
As displayed in Fig. 1, SIH was significantly associated with higher risk of MACCE occurrence during a median follow-up of 1.7 years (Log-rank p < 0.01). Cox regression analysis identified SIH as a significant predictor of MACCE univariably (HR = 1.92, 95% CI 1.19–3.01) and after multivariable adjustment (adjusted
HR = 1.802, 95% CI 1.01–3.21). The multivariable hazard model was adjusted for: age, gender, BMI, heart rate, smoking, DM, dyslipidemia, CKD, number of diseased arteries, distal embolization, LTB, angiographically evident residual thrombus, and post-procedural TIMI Flow. Table 4 summarizes the occurrence of each individual outcome according to the presence of SIH.

**Discussion**

This is the first study to investigate the association between SIH and multiple angiographic predictors of poor clinical outcomes in patients with STEMI undergoing PPCLI. In addition, this study demonstrates that SIH is significantly associated with worse long-term prognosis irrespective of the presence of diabetes.
|                  | Distal embolization | Large thrombus burden | Pre-procedural TIMI flow < 1 |
|------------------|----------------------|------------------------|-----------------------------|
|                  | aOR 95% CI           | P-value                | aOR 95% CI                  | P-value                | aOR 95% CI                  | P-value |
| Age              | 1.022 (0.997–1.048)  | 0.075                  | 1.017 (0.994–1.040)         | 0.141                  | 1.012 (0.990–1.035)         | 0.300   |
| Male gender      | 1.435 (0.742–2.778)  | 0.275                  | 1.483 (0.795–2.765)         | 0.216                  | 1.130 (0.606–2.107)         | 0.700   |
| Hypertension     | 1.337 (0.731–2.445)  | 0.343                  | 0.901 (0.519–1.565)         | 0.711                  | 1.457 (0.844–2.513)         | 0.176   |
| DM               | 1.098 (0.545–2.211)  | 0.801                  | 0.875 (0.439–1.743)         | 0.703                  | 1.710 (0.841–3.477)         | 0.139   |
| Dyslipidemia     | 1.008 (0.535–1.901)  | 0.470                  | 0.805 (0.448–1.448)         | 0.470                  | 0.623 (0.345–1.125)         | 0.116   |
| Smoking          | 1.200 (0.659–2.186)  | 0.554                  | 1.751 (1.022–3.001)         | **0.041**              | 1.139 (0.669–1.939)         | 0.630   |
| CKD              | 0.315 (0.054–1.841)  | 0.144                  | 0.224 (0.039–1.285)         | 0.093                  | 2.393 (0.504–11.369)        | 0.272   |
| PAD              | 0.854 (0.158–4.622)  | 0.731                  | 1.348 (0.317–5.729)         | 0.686                  | 2.006 (0.439–9.159)         | 0.369   |
| BMI              | 1.020 (0.987–1.053)  | 0.120                  | 1.031 (0.985–1.080)         | 0.191                  | 0.988 (0.957–1.019)         | 0.447   |
| SIH              | 2.706 (1.506–4.863)  | **0.002**              | 2.171 (1.270–3.709)         | **0.005**              | 2.690 (1.435–5.041)         | <0.001  |

DM: diabetes mellitus; CKD: chronic kidney disease; PAD: peripheral arterial disease; BMI: body mass index; SIH: stress induced hyperglycemia

Each column represents a different multivariable regression model for each dependent predictor (1: Distal embolization, 2: Large thrombus burden, and 3: Pre-procedural TIMI flow < 1). Each row represents a different independent predictor. Statistically significant results are marked in bold.

![Fig. 1](Image)  
**Fig. 1** Kaplan Meier survival curve for the occurrence of any major adverse cardiovascular event according to the presence of stress induced hyperglycemia with or without diabetes.
Mortality and stroke rates were higher in SIH patients, while cardiac hospitalization and major bleeding events did not differ significantly between patients with and without SIH. A previous study reported increased incidence of cardiac hospitalization among non-diabetic patients with STEMI and SIH [24]. However, a different definition of SIH was used in that study.

Emerging evidence outlines the strong and independent association of SIH with short- and long-term clinical outcomes in STEMI patients irrespective of the definition used for the diagnosis of SIH [3, 5, 25, 26]. However, the exact mechanisms of this correlation are not fully understood. Considering that SIH is linked with adverse angiographic outcomes based on an appealing biological hypothesis as mentioned above, the worse clinical outcomes in SIH patients could, in part, be explained by the higher incidence of angiographic predictors of adverse clinical events before PPCI.

Indeed, our study revealed that patients with STEMI and SIH with or without diabetes were almost three times more likely to have poor pre-procedural TIMI flow. This finding is in line with other findings from previous studies that reported the strong association between SIH and poor pre-procedural TIMI flow [27]. Of note, DM was not associated with poor pre-procedural TIMI flow, even though STEMI patients with DM have worse clinical outcomes [28, 29]. This finding could possibly indicate that SIH might be a major driver of augmented prothrombotic and inflammatory burden during STEMI even in patients with chronic DM.

In this study, almost 6 out of 10 patients with STEMI and concomitant SIH had LTB. It must be emphasized that SIH with or without DM was an independent predictor of LTB after adjusting for clinical risk factors strongly linked with higher intracoronary thrombus burden. Other studies have also verified the strong correlation between SIH and LTB in patients presenting with STEMI [16, 30]. These findings could be explained by the fact that thrombus formation and SIH share common pathophysiology. Specifically, during STEMI oxidative stress from metabolic derangements, including stress hyperglycemia, leads to endothelial injury. Endothelial dysfunction causes decreased nitric oxide availability and disruption of the endothelial cell lining [31]. All these mechanisms give rise to increased adhesion of inflammatory molecules, prothrombotic factors and platelet activation intensifying the formation of thrombus [32]. However, whether SIH is causally related to increased thrombogenicity in patients with STEMI remains to be clarified in future studies.

Regarding other angiographic findings, SIH was significantly associated with more frequent distal embolization. This could be attributed to the fact that distal embolization occurs more often in the presence of LTB during PPCI [33].

The existence of residual thrombus and poor post-procedural TIMI flow did not differ between STEMI patients with and without SIH. The significance of the reported findings is highlighted by the fact that poor procedural TIMI flow during PPCI, LTB and distal embolization are all determinants of larger infract size, lower left ventricular ejection fraction and MACCE [34–36].

Therefore, early identification of those high-risk patients before PPCI is important, as they might benefit from more aggressive therapies, such as use of IIb/IIIa inhibitors and thrombus aspiration. Indeed, a recent study provided evidence of a mortality benefit among STEMI patients with SIH who underwent TA during PPCI, suggesting that the mere quantitative evaluation of thrombus burden cannot adequately identify patient subgroups, who might benefit from mechanical thrombus removal [13].

### Study limitations

Our study has several limitations. Firstly, this was a non-randomized observational cohort study, and all patients were enrolled in a single center, suggesting that potential unknown confounders and selection bias could have influenced the results. Secondly, the diagnosis of SIH was established based on the AHA criteria and all patients reported fasting for at least 8 h before inclusion. However, recent evidence suggests that stress induced hyperglycemia ratio (SIHR) could be a better indicator of stress hyperglycemia especially in diabetic patients. Still, HbA1C% is not always available in the time constraint setting of STEMI, and therefore the diagnosis of SIH based on the definition of SIHR before PPCI is not always feasible. Moreover, intracoronary imaging was not performed. Hence, the presence of intracoronary residual thrombus was based on visual examination of the coronary angiograms.

### Table 4: Follow-up outcomes by the presence of stress induced hyperglycemia

|                  | Without SIH N (%) | SIH N (%) | P value* |
|------------------|-------------------|-----------|----------|
| Stroke           | 0 (0%)            | 2 (1.70%) | 0.032    |
| Cardiac hospitalisation | 7 (3.70%)        | 4 (3.30%) | 0.660    |
| Bleeding         | 5 (2.70%)         | 4 (2.50%) | 0.340    |
| Death            | 22 (11.70%)       | 31 (25.60%) | 0.002   |
| MACCE            | 32 (17%)          | 37 (30.60%) | 0.005   |
In conclusion, SIH in STEMI patients undergoing PPCI appears to be associated with poor pre-procedural TIMI flow, LTB, and distal embolization and linked to increased incidence of MACCE. Although the hyperglycemic milieu seems to play a pivotal role in the regulation of oxidative stress and the prothrombotic and inflammatory burden in the STEMI setting, SIH is not currently perceived as an independent risk enhancer in patients with STEMI. Investigating SIH as an additional risk factor in traditional risk scores could facilitate risk-stratification and potentially suggest novel therapeutic targets, promoting personalized care in STEMI patients. Larger and prospective studies are warranted to confirm these proof-of-concept findings.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01578-6.

Additional file 1: Figure S1. Flow-diagram.

Acknowledgements
This research has been co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH–CREATE–INNOVATE (project code: T1EDK-04005).

Author contributions
NS and BK contributed to the conception of the work. NS, BK, ASP, DM, VP, GSo, and GSI contributed to data collection. NS and ASP drafted the manuscript. EP conducted the statistical analysis. TK, SD, VA and GG revised the manuscript. All authors read and approved the manuscript.

Funding
The specific project has been co-financed through the call for Proposals for the Action “Competitiveness, entrepreneurship & innovation” in the framework of the Operational Programme “Research, Create, Innovate” (project code: T1EDK-04005) of the Partnership Agreement for the Development Programme 2014–2020 by the European Social Fund (ESF) and Greek National funds. The project has undergone peer review and has been approved for funding, being awarded a grant of 873,821.00 €. The funder had no role in the design or conduct of the study, preparation, review or approval of the manuscript and decision to submit the manuscript for publication.

Availability of data and materials
Data and study materials are available upon request.

Declarations

Ethics approval and consent to participate
The study was conducted in accordance with the Declaration of Helsinki. The study was approved by ethics board of AHEPA Hospital (Protocol number 321/2019), and informed consent was obtained from all individual participants.

Consent for publication
The manuscript was approved by all authors for publication.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details
1 First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiranakid 1, 54636 Thessaloniki, Greece. 2 Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. 3 Biomics_Auth, Bioanalysis and Omics Lab, Centre for Interdisciplinary Research of Aristotle University of Thessaloniki, Innovation Area of Thessaloniki, 57001 Thermi, Greece. 4 Pathology Department, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Received: 2 June 2022   Accepted: 21 July 2022
Published online: 26 July 2022

References
1. Roberts GW, Quinn SJ, Valentine N, et al. Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycaemia ratio. J Clin Endocrinol Metab. 2015;100:4490–7. https://doi.org/10.1210/jc.2015-2660.
2. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117:1610–9. https://doi.org/10.1161/ CIRCULATIONAHA.107.188629.
3. Chen G, Li M, Wen X, et al. Association between stress hyperglycemia ratio and in-hospital outcomes in elderly patients with acute myocardial infarction. Front Cardiovasc Med. 2021;8:698725.
4. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773–8. https://doi.org/10.1016/S0140-6736(00)04159-9.
5. Xu W, Yang Y, Zhu J, et al. Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment elevation myocardial infarction: insights from a multi-center observational study. Cardiovasc Diabetol. 2022;21:48. https://doi.org/10.1186/s12933-022-01479-8.
6. Li M, Chen G, Feng Y, He X. Stress induced hyperglycemia in the context of acute coronary syndrome: definitions, interventions, and underlying mechanisms. Front Cardiovasc Med. 2021;8:676892.
7. Bauters C, Ennezat PV, Tricot O, et al. Stress hyperglycaemia is an independent predictor of left ventricular remodelling after first anterior myocardial infarction in non-diabetic patients. Eur Heart J. 2007;28:546–52. https://doi.org/10.1093/eurheartj/ehl546.
8. Stegenga ME, van der Crabben SN, Blümer RME, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood. 2008;112:82–9. https://doi.org/10.1182/blood-2007-11-121723.
9. Bar-Or D, Rael LT, Madaayg RV, et al. Stress hyperglycemia in critically ill patients: insight into possible molecular pathways. Front Med. 2019;6:54. https://doi.org/10.3389/fmed.2019.00054.
10. Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol off J Polish Physiol Soc. 2019. https://doi.org/10.26402/jpp.2019.601.
11. Malmberg K, Rydén L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650–61. https://doi.org/10.1093/euheartj/ehi199.
12. Cheung NW, Wong VW, McLean M. The Hyperglycaemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29:765–70. https://doi.org/10.2337/diacare.29.04.06.dc05-1894.
13. Sandu C, Barbieri M, Balestrieri ML, et al. Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up. Cardiovasc Diabetol. 2018;17:152. https://doi.org/10.1186/s12933-018-0795-8.
14. Arslan F, Bongartz L, Ten Berg JM, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group. Neth Heart J. 2018;26:417–21. https://doi.org/10.1007/s12471-018-1134-0.
15. Khalfallah M, Abdelmagedd R, Elgendy E, Hafez YM. Incidence, predictors and outcomes of stress hyperglycemia in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary
16. Chu J, Tang J, Lai Y, et al. Association of stress hyperglycemia ratio with intracoronary thrombus burden in diabetic patients with ST-segment elevation myocardial infarction. J Thorac Dis. 2020;12:6598–608. https://doi.org/10.21037/jtd-20-2111.

17. Karagiannidis E, Sofidis G, Papazoglou A, et al. Correlation of the severity of coronary artery disease with patients’ metabolic profile-rationale, design and baseline patient characteristics of the CorLipid trial. BMC Cardiovasc Disord. 2021;21:79. https://doi.org/10.1186/s12872-021-01865-2.

18. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal definition of myocardial infarction (2018). Circulation. 2018;138:e618–51. https://doi.org/10.1161/CIR.0000000000000617.

19. Corrigendum to. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 40:3096https://doi.org/10.1093/eurheartj/ehz507.

20. Sianos G, Papafaklis M, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010;22:68–148.

21. Sianos G, Papafaklis M, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50:573–83. https://doi.org/10.1016/j.jacc.2007.04.059.

22. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. J Am Med Assoc. 2012;307:1817–26. https://doi.org/10.1001/jama.2012.421.

23. Ramjane K, Han L, Jin C. The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention. Exp Clin Cardiol. 2008;13:121–8.

24. Kojima T, Hikosa S, Nakatani D, et al. Impact of hyperglycemia on long-term outcome in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2020;125:851–9. https://doi.org/10.1016/j.amjcard.2019.12.034.

25. Khaffafah M, Abdelmageed R, Elgendy E, Hafez YM. Incidence, predictors and outcomes of stress hyperglycemia in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Diabetes Vasc Dis Res. 2020;17:1479164119883983. https://doi.org/10.1177/1479164119883983.

26. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucose normalization and adverse consequences of thrombus during PCI. J Am Med Assoc. 2012;307:1817–26. https://doi.org/10.1001/jama.2012.421.

27. Timmer JR, Ottervanger JP, De Boer MJ, et al. Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005;45:999–1002. https://doi.org/10.1016/j.jacc.2004.12.050.

28. Simsek S, Motovska Z, Hlinomaz O, et al. The effect of diabetes on prognosis following myocardial infarction treated with primary angioplasty and potent antplatelet therapy. J Clin Med. 2020. https://doi.org/10.3390/jcm9082555.

29. Jensen LO, Maeng M, Thaysen P, et al. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109:629–35. https://doi.org/10.1016/j.amjcard.2011.10.018.

30. Sigirici S, Yildiz SS, Keskin K, et al. The predictive value of stress hyperglycemia on thrombus burden in non-diabetic patients with ST-segment elevation myocardial infarction. Blood Coagul fibrinolysis an Int J Haemost 2019;30:270–6. https://doi.org/10.1097/MBC.0000000000000832.

31. Srikantz S, Ambrose JA. Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI. Curr Cardiol Rev. 2012;8:168–76. https://doi.org/10.2174/157340312803217247.

32. Quyyumi AA. Prognostic value of endothelial function. Am J Cardiol. 2003;91:19–24. https://doi.org/10.1016/S0002-9149(03)00430-2.

33. Napodano M, Ramondo A, Tanantii G, et al. Predictors and time-related impact of distal embolization during primary angioplasty. Eur Heart J. 2009;30:305–13. https://doi.org/10.1093/eurheartj/ehn594.

34. Lee E, Kirtane AJ. Distal embolisation in acute myocardial infarction. Interv Cardiol Rev Resour. 2007. https://doi.org/10.15420/icr.2007.49.

35. Schaf M, Mewton N, Ricufol G, et al. Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients. J Cardiol. 2016;67:248–53. https://doi.org/10.1016/j.jcc.2015.05.008.

36. Scarparo P, van Gamen M, Wilschut J, et al. Impact of thrombus burden on long-term clinical outcomes in patients with either anterior or non-anterior ST-segment elevation myocardial infarction. J Thromb Thrombolysis. 2021. https://doi.org/10.1007/s11399-021-02603-3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.